Analysis of Risk Factors for MACE in Type 2 Diabetic Patients with Obesity after Glimepiride Therapy
Objective:To investigate the independent factors associated with major adverse cardiovascular events (MACE) in type 2 diabetes mellitus (T2DM) patients with obesity after glimepiride therapy and establish a clinical prediction model for validation. Meth-ods:A total of 206 T2DM patients with obesity were collected from April 2020 to April 2022 with 2 years of follow-up. The patients were divided into two groups according to the presence of MACE,namely the occurrence group (n=25,with MACE) and nonoccurrence group (n=181,without MACE). After comparing the general data of the two groups,binary Logistic regression analysis was performed to ana-lyze the independent factors affecting the occurrence of MACE,and then model validation was vsed.Results:After binary Logistic regres-sion analysis,age>60 years old (OR=3.532),disease duration>5 years (OR=3.513),BMI>30.0 kg·m-2 (OR=3.190),hypoglyce-mia (OR=2.902),poor treatment compliance (OR=0.295),and dose>2 mg·d-1 (OR=3.253) were independent factors affecting the occurrence of MACE in T2DM patients with obesity (P<0.05). The nomogram was constructed from independent factors,the C-index of the calibration curve was 0.99,the absolute error of agreement between the true and predicted values was 0.016,the predic-tion model AUC was 0.850,and the 95％ CI was 0.785～0.915. Conclusion:In T2DM patients with obesity,the occurrence of MACE after glimepiride therapy is affected by the dosage,treatment compliance,hypoglycemia,disease duration,and age,so the interventions targeting risk factors are needed to reduce the incidence of MACE.
Type 2 diabetes mellitusObesityGlimepirideCardiovascular adverse eventsPredictive model
万方数据
维普
